AR-148 / Y-Biologics - LARVOL DELTA

Wybiologics presents research results related to tumor microenvironment at the American Society for Immuno-Oncology [Google translation] (BioTimes) - "Antibody drug development platform company Y-Biologics...announced on the 7th that two research results presentations (posters) on pipelines related to the tumor microenvironment, including AR148, were accepted at the Society for Immunotherapy of Cancer 2024 (SITC) in the United States....Wybiologics announces the release of ‘TGFβ SelecTrap (AR148),’ a new drug candidate that selectively inhibits TGFβ, one of the main causative agents that suppresses the activity of immune cells in the tumor microenvironment....Another research result announcement is about 'AR092 (HLA-G/CD3 T cell engager)', one of the 'T cell bispecific antibody' pipelines."

Preclinical • Oncology